阿柏西普联合雷珠单抗治疗效果欠佳的糖尿病黄斑水肿的疗效分析  

Curative Effect of Aflibercept Combined with Ranibizumab in the Treatment of Diabetic Macular Edema

作　　者：袁金[1] 李慧[1] 刘桂池 车玥 YUAN Jin;LI Hui;LIU Guichi;CHE Yue(Department of Ophthalmology,the Sixth Affiliated Hospital of Guangzhou Medical University(Qingyuan People's Hospital),Qingyuan,Guangdong Province,511500 China;Department of General Internal Medicine,Sinopharm Gezhouba Central Hospital,Yichang,Hubei Province,443000 China)

机构地区：[1]广州医科大学第六附属医院(清远市人民医院)眼科,广东清远511500 [2]国药葛洲坝中心医院综合内科,湖北宜昌443000

出　　处：《糖尿病新世界》2024年第6期184-187,共4页Diabetes New World Magazine

摘　　要：目的探讨阿柏西普联合雷珠单抗治疗效果欠佳的糖尿病黄斑水肿患者的效果。方法回顾性选取2021年9月—2022年9月广州医科大学第六附属医院收治的90例糖尿病黄斑水肿患者的临床资料,依据用药方案不同分为两组。对照组(n=45,均为单侧眼病变)用雷珠单抗持续治疗,观察组(n=45,均为单侧眼病变)用雷珠单抗联合阿柏西普治疗。比较两组治疗后的视力、眼压、视网膜厚度、不良反应发生情况。结果观察组在治疗前的视力、黄斑中心厚度、眼压与单一组比较,差异无统计学意义(P均>0.05)。治疗后,观察组的视力较对照组明显提高,观察组的黄斑中心凹厚度和眼压对比对照组明显降低,差异有统计学意义(P均<0.05)。两组不良反应发生情况对比,差异无统计学意义(P>0.05)。结论对于雷珠单抗治疗效果欠佳的糖尿病黄斑水肿患者,雷珠单抗联合阿柏西普治疗对患者的视力提高作用明显,对视网膜结构的改善成效突出,治疗安全有效。Objective To investigate the efficacy of Aflibercept combined with Ranibizumab in the treatment of diabetic macular edema.Methods Clinical data of 90 patients with diabetic macular edema who were admitted to the Sixth Affiliated Hospital of Guangzhou Medical University from September 2021 to September 2022 were retrospective selected.According to the difference of medication,they were divided into two groups.The control group(n=45,all unilateral eye lesions)received Ranibizumab continued treatment.The observation group(n=45,all with unilateral ocular lesions)received Ranibizumab combined with Aflibercept.Baseline visual acuity,intraocular pressure,retinal thickness were compared after treatment and incidence of adverse reaction.Results There was no statistically significant difference between the observation group and the control group in visual acuity,macular central thickness and intraocular pressure before treatment(all P>0.05).After treatment,the visual acuity ratio in the observation group was significantly higher than that in the control group.The macular central thickness and intraocular pressure in the observation group were significantly lower than those in the control group,and the differences were statistically significant(both P<0.05).There was no statistically significant difference between two groups in incidence of adverse reaction(P>0.05).Conclusion For Diabetic macular edema patients with poor treatment effect of Ranibizumab,the combination of Aflibercept will improve the visual acuity of patients and improve the retinal structure,the alternative therapy of Aflibercept is safe,effective.

关 键 词：糖尿病黄斑水肿 雷珠单抗 阿柏西普 效果欠佳 治疗 

分 类 号：R4[医药卫生—临床医学]